June 22, 2020 / 1:35 PM / 16 days ago

BRIEF-Transgene’s, Bioinvent’s BT-001 Achieves High Tumor Cure Rates In Preclinical Models

June 22 (Reuters) - Transgene SA:

* TRANSGENE’S AND BIOINVENT’S BT-001 ACHIEVES OUTSTANDING TUMOR CURE RATES IN PRECLINICAL MODELS

* PROOF OF CONCEPT FOR NOVEL ONCOLYTIC VIRUS WITH DIFFERENTIATED ANTI-CTLA4 ANTIBODY

* SIGNIFICANT ANTITUMOR ACTIVITY OF BT-001 SEEN IN SEVERAL IMMUNOCOMPETENT MODELS

* TREATMENT WITH BT-001 ALSO INDUCED A SPECIFIC AND LONG-LASTING IMMUNE MEMORY, WHICH IS THOUGHT TO ACT ON DISTANT TUMORS AND TO PREVENT POTENTIAL RELAPSE

* PHASE I CLINICAL TRIAL WITH BT-001 EXPECTED TO START BEFORE END OF 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below